Risk factors of cardiovascular disease mortality in maintenance hemodialysis patients

doi:10.3969/j.issn.1673-8640.2017.06.009

Abstract

Abstract:

Objective To investigate the risk factors of cardiovascular disease （CVD） mortality in maintenance hemodialysis （MHD） patients. Methods A total of 452 patients with MHD were enrolled. Total cholesterol （TC）,high-density lipoprotein cholesterol （HDL-C）,low-density lipoprotein cholesterol （LDL-C）,apolipoprotein A1 （apo A1）,apolipoprotein B （apo B）,lipoprotein a [Lp（a）],homocysteine （Hcy）,N-terminal B-type natriuretic peptide （NT-proBNP）,cardiac troponin I （cTnI） and high-sensitivity C-reactive protein （hs-CRP） were determined before dialysis. According to CVD mortality,MHD patients were classified into mortality group and non-mortality group,and the risk factors of CVD mortality were analyzed. Results The levels of NT-proBNP and hs-CRP in mortality group were higher than those in non-mortality group（P<0.05）,and the levels of TC and LDL-C were lower（P<0.05）. There was no statistical significance for the other parameters between the 2 groups （P>0.05）. Logistic regression analysis showed that NT-proBNP and hs-CRP were risk factors for CVD mortality in MHD patients [odds ratio（OR）=5.698,95% confidence interval（CI）1.908-17.014,P=0.002;OR=3.653,95%CI 1.249-10.165,P=0.018]. Conclusions There are some differences for the risk factors of CVD mortality between MHD patients and general population. NT-proBNP and hs-CRP may be independent risk factors for CVD mortality in MHD patients.

Key words: Risk factor, Hemodialysis, Cardiovascular disease

CLC Number:

R446.1

GU Feng. Risk factors of cardiovascular disease mortality in maintenance hemodialysis patients[J]. Laboratory Medicine, 2017, 32(6): 486-489.

Figures/Tables 2

References 24

[1]	Abstracts of the 4th Annual International Conference of the Saudi Society of Nephrology[J]. Saudi J Kidney Dis Transpl,2009,20(5):891-939.
[2]	KALANTAR-ZADEH K,ABBOTT K C,KRONENBERG F,et al.Epidemiology of dialysis patients and heart failure patients[J]. Semin Nephrol,2006,26(2):118-133.
[3]	COLLINS A J,KASISKE B,HERZOG C,et al. Excerpts from the United States Renal Data System2003 Annual Data Report:atlas of end-stage renal disease in the United States[J]. Am J Kidney Dis,2003,45(1 Suppl 1):A5-A7,S1-S230.
[4]	HOU F,JIANG J,CHEN J,et al.China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis[J]. BMC Nephrol,2012,13:94.
[5]	WATTANAKIT K,CUSHMAN M,STEHMAN-BREEN C,et al.Chronic kidney disease increases risk for venous thromboembolism[J]. J Am Soc Nephrol,2008,19(1):135-140.
[6]	MOODY W E,EDWARDS N C,MADHANI M,et al.Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?[J]. Atherosclerosis,2012,223(1):86-94.
[7]	SARNAK M J,LEVEY A S,SCHOOLWERTH A C,et al.Kideny disease as a risk factor for development of cardiovascular disease:a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease,High Blood Pressure Research,Clinical Cardiology,and Epidemiology and Prevention[J]. Circulation,2003,108(17):2154-2169.
[8]	贾凤玉,孟建中. 慢性肾脏病(透析)患者的心血管疾病诊疗指南解读[J]. 中国血液净化,2011,10(10):570-575.
[9]	ANDERSON K M,CASTELLI W P,LEVY D.Cholesterol and mortality. 30 years of follow-up from the Framingham study[J]. JAMA,1987,257(16):2176-2180.
[10]	沈晓洁,吴灏,余日臻,等. 血液透析患者营养状况与逆流行病学现象的探讨[J]. 第二军医大学学报,2015,36(1):14-18.
[11]	李芹. 维持性血液透析患者死亡原因及危险因素分析[D]. 泸州:泸州医学院,2014.
[12]	段绍霞,蔡宏,张伟明,等. 维持性血液透析患者营养不良-炎症复合体综合征与预后的关系研究[J]. 上海交通大学学报(医学版),2015,35(12):1851-1857.
[13]	LIU Y,CORESH J,EUSTACE J A,et al.Association between cholesterol level and mortality in dialysis patient:role of inflammation and malnutrition[J]. JAMA,2004,291(4):451-459.
[14]	COLLADO S,COLL E,DEULOFEU R,et al.Prevalence of cardiovascular disease in uraemia and relevance of cardiovascular risk factors[J]. Nefrologia,2010,30(3):342-348.
[15]	魏娜,刘秀娟,尹秀英,等. 维持性血液透析心血管事件与脂质代谢紊乱的关系[J]. 南昌大学学报(医学版),2015,60(1):59-61.
[16]	SILBERNAGEL G,GENSER B,DRECHSLER C,et al.HDL cholesterol,apolipoproteins,and cardiovascular risk in hemodialysis patients[J]. J Am Soc Nephol,2014,26(2):484-492.
[17]	ELMACHTANI IDRISSI S,DAMI A,BOUHSAIN S,et al.Lipid profile of patients on chronic hemodialysis(Morocco)[J]. Sante,2011,21(1):27-31.
[18]	王宁宁. 尿毒症患者血管钙化的组织学研究及相关分子机制的探讨[D]. 南京:南京医科大学,2006.
[19]	吕玉凤,刘必成. 透析患者心血管疾病危险因素的逆流行病学现象[J]. 中华肾脏病杂志,2006,22(3):183-186.
[20]	BARADARI A G,EMAMI ZEYDI A,ESPAHBODI F,et al.Evaluation of serum C-reactive protein level and its related factors in hemodialysis patients in Sari,Iran[J]. Pak J Biol Sci,2011,14(10):595-599.
[21]	YE X,WEI L,PEI X,et al.Application of creatinine- and/or cystatin C-based glomerular filtration rate estimation equations in elderly Chinese[J]. Clin Interv Aging,2014,9:1539-1549.
[22]	莫惠芳,吴炯,宋斌斌,等. NT-proBNP在心血管疾病高危人群中长期预后的作用[J]. 检验医学,2014,29(10):1013-1018.
[23]	朱笑频,王成刚. NT-proBNP和cTnI联合检测在急诊心力衰竭患者诊治中的应用[J]. 检验医学,2013,28(1):30-32.
[24]	CODOGNOTTO M,PICCOLI A,ZANINOTTO M,et al.Effect of a dialysis session on the prognostic values of NT-proBNP,troponins,endothelial damage and inflammation biomarkers[J]. J Nephrol,2010,23(4):465-471.

组别	例数	年龄（岁）		TC （mmol/L）	HDL-C （mmol/L）		LDL-C （mmol/L）	apo A1 （g/L）
CVD死亡组	19	66.1±14.7		3.84±0.76^*	0.98±0.25		1.97±0.67^*	1.19±0.19
未死亡组	433	59.4±14.3		4.41±1.16	1.08±0.32		2.63±1.03	1.24±0.27
组别	apo B （g/L）		Lp（a）（mg/L）			Hcy （μmol/L）		hs-CRP （mg/L）	cTnI （ng/mL）	NT-proBNP （pg/mL）
CVD死亡组	0.73±0.17		155.0（103.2~239.7）			28.9（19.8~35.9）		9.9（5.5~25.4）^*	0.067（0.035~0.151）	18 091.5 （10 959.5~35 000.0）^*
未死亡组	0.85±0.25		199.0（101.0~370.9）			32.7（23.4~51.6）		3.0 （1.1~6.8）	0.049（0.034~0.080）	3 496.2 （1 857.0~7 908.5）

组别	例数	年龄（岁）		TC （mmol/L）	HDL-C （mmol/L）		LDL-C （mmol/L）	apo A1 （g/L）
CVD死亡组	19	66.1±14.7		3.84±0.76^*	0.98±0.25		1.97±0.67^*	1.19±0.19
未死亡组	433	59.4±14.3		4.41±1.16	1.08±0.32		2.63±1.03	1.24±0.27
组别	apo B （g/L）		Lp（a）（mg/L）			Hcy （μmol/L）		hs-CRP （mg/L）	cTnI （ng/mL）	NT-proBNP （pg/mL）
CVD死亡组	0.73±0.17		155.0（103.2~239.7）			28.9（19.8~35.9）		9.9（5.5~25.4）^*	0.067（0.035~0.151）	18 091.5 （10 959.5~35 000.0）^*
未死亡组	0.85±0.25		199.0（101.0~370.9）			32.7（23.4~51.6）		3.0 （1.1~6.8）	0.049（0.034~0.080）	3 496.2 （1 857.0~7 908.5）

相关因素	B值	标准误	Wald值	P值	OR值	95%CI
NT-proBNP	1.740	0.558	9.720	0.002	5.698	1.908~17.014
hs-CRP	1.271	0.535	5.643	0.018	3.653	1.249~10.165
常量	-11.478	2.465	21.685	0.000	0.000

相关因素	B值	标准误	Wald值	P值	OR值	95%CI
NT-proBNP	1.740	0.558	9.720	0.002	5.698	1.908~17.014
hs-CRP	1.271	0.535	5.643	0.018	3.653	1.249~10.165
常量	-11.478	2.465	21.685	0.000	0.000